CN101801915A - Method for synthesizing beta-sodium alanine and calcium pantothenate - Google Patents
Method for synthesizing beta-sodium alanine and calcium pantothenate Download PDFInfo
- Publication number
- CN101801915A CN101801915A CN200880101427A CN200880101427A CN101801915A CN 101801915 A CN101801915 A CN 101801915A CN 200880101427 A CN200880101427 A CN 200880101427A CN 200880101427 A CN200880101427 A CN 200880101427A CN 101801915 A CN101801915 A CN 101801915A
- Authority
- CN
- China
- Prior art keywords
- alanine
- beta
- sodium
- pantothenate
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/26—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing carboxyl groups by reaction with HCN, or a salt thereof, and amines, or from aminonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本发明涉及从β-氨基-丙腈制备β-丙氨酸钠的方法。The invention relates to a method for preparing sodium beta-alanine from beta-amino-propionitrile.
β-丙氨酸钠是用于通过将丙氨酸盐分别与L-或DL-泛内酯反应制备D-或DL-泛酸钠或D-或DL-泛酸钙的中间产物。Sodium β-alanine is an intermediate product used in the preparation of sodium D- or DL-pantothenate or calcium D- or DL-pantothenate by reacting alanine salt with L- or DL-pantolactone, respectively.
US 4,258,210描述了从β-氨基丙腈制备晶体D-泛酸钠的方法,其中用水性氢氧化钠皂化β-氨基丙腈以产生β-丙氨酸钠溶液,在两步骤的干燥过程中获得水含量1%的干燥的β-丙氨酸钠,将干燥的β-丙氨酸钠溶于低级链烷醇溶剂中并使其与L-泛内酯反应,产生晶体D-泛酸钠。然而已证明,为了获得纯度适用于人消耗的D-泛酸钠,进一步的结晶作用是必需的。US 4,258,210 describes a process for the preparation of crystalline sodium D-pantothenate from β-aminopropionitrile, in which β-aminopropionitrile is saponified with aqueous sodium hydroxide to produce a solution of sodium β-alaninate, and water is obtained in a two-step drying process 1% dry sodium beta-alanine, which is dissolved in a lower alkanol solvent and reacted with L-pantolactone to produce crystalline sodium D-pantothenate. However, further crystallization has proven to be necessary in order to obtain sodium D-pantothenate of a purity suitable for human consumption.
除无机离子之外,污染根据背景技术方法获得的β-丙氨酸钠的主要杂质来自于β-氨基丙腈的水性氢氧化钠皂化,即盐形式的二-(2-羧乙基)-胺(也称作亚氨基-二-丙酸(IDPA))和β-丙氨酰-β-丙氨酸(分别为I和II)。尽管胺I不与泛内酯反应,但是二肽II与L-泛内酯反应,得到D(+)-N-(2,4-二羟基-3,3-二甲基丁酰基)-β-丙氨酰-β-丙氨酸(III)。In addition to inorganic ions, the main impurity that contaminates the sodium β-alanine obtained according to the background art method comes from the aqueous sodium hydroxide saponification of β-aminopropionitrile, that is, di-(2-carboxyethyl)- Amine (also known as imino-di-propionic acid (IDPA)) and β-alanyl-β-alanine (I and II, respectively). Although amine I does not react with pantolactone, dipeptide II reacts with L-pantolactone to give D(+)-N-(2,4-dihydroxy-3,3-dimethylbutyryl)-β - Alanyl-β-alanine (III).
考虑到对用于人消耗的高纯度D-泛酸钙的日益增长的需求,需要进一步改进上述方法并开发高纯度晶体D-泛酸钠和D-泛酸钙的非常经济的高产率合成,即不需要额外的结晶作用。Considering the increasing demand for high-purity calcium D-pantothenate for human consumption, there is a need to further improve the above method and develop a very economical high-yield synthesis of high-purity crystalline sodium D-pantothenate and calcium D-pantothenate that does not require Additional crystallization.
因此,本发明涉及由β-氨基-丙腈制备能用于与R-泛内酯缩合成D-泛酸盐的β-丙氨酸钠的改进方法,所述方法获得作为醇溶液的β-丙氨酸钠,其改进包括:The present invention therefore relates to an improved process for the preparation of β-alaninate sodium usable for condensation with R-pantolactone to D-pantothenate from β-amino-propionitrile, which method obtains β-alaninate as an alcoholic solution. Sodium Alaninate, whose improvements include:
(a)在碱性水性介质或醇/水混合物中进行β-氨基-丙腈的水解,然后(a) carry out the hydrolysis of β-amino-propionitrile in alkaline aqueous medium or alcohol/water mixture, then
(b)将溶剂替换为醇,使得最终的β-丙氨酸盐混合物仅以下述量含有副产物(side-products)或副产品(by-products),所述量对D-泛酸盐品质无不利影响。(b) replacing the solvent with an alcohol such that the final β-alanine salt mixture contains only side-products or by-products in amounts that have no effect on the quality of D-pantothenate Negative Effects.
皂化可以在水中或者水与一种或多种醇的混合物中进行。需要时可以通过使用或不使用夹带剂的蒸馏,以本身已知的方式去除水。术语“替换”包括部分或完全去除原始溶剂。这表示最终获得β-丙氨酸钠的醇溶液,其可直接与L-泛内酯反应,得到纯的D-泛酸钠,所述D-泛酸钠又可以被转化为D-泛酸钙,后者满足在人食品中使用或用作药物的规格要求。这更特定地意味着,例如泛解酸钙(calcium pantoate)的含量少于0.80%(w/w),且泛酸酰-β-丙氨酰-β-丙氨酸钙(calcium panto-β-alanyl-β-alaninate)(III的钙盐)的含量少于0.10%(w/w)。Saponification can be carried out in water or a mixture of water and one or more alcohols. Water can be removed in a manner known per se by distillation with or without entraining agent, if desired. The term "replacement" includes partial or complete removal of the original solvent. This means that the alcohol solution of sodium β-alanine is finally obtained, which can directly react with L-pantolactone to obtain pure sodium D-pantothenate, which can be converted into calcium D-pantothenate again, and then or meet the specification requirements for use in human food or as a drug. This means more specifically that, for example, calcium pantoate contains less than 0.80% (w/w) and calcium panto-β-alanyl-β-alanine The content of alanyl-β-alaninate) (calcium salt of III) is less than 0.10% (w/w).
更特定地,本发明的经改进的方法包括:More specifically, the improved method of the present invention comprises:
(a)在60-95℃的温度下,向过量的氢氧化钠在水或醇/水中的溶液中添加β-氨基-丙腈,需要时进一步加热混合物并除去水;(a) adding β-amino-propionitrile to a solution of excess sodium hydroxide in water or alcohol/water at a temperature of 60-95° C., heating the mixture further and removing water if necessary;
(b)用β-丙氨酸中和过量的氢氧化钠,避免β-丙氨酸的大幅过量,以直接获得具有期望浓度的溶液;(b) neutralizing excess sodium hydroxide with β-alanine, avoiding a substantial excess of β-alanine, to directly obtain a solution with the desired concentration;
(c)去除水,和(c) remove water, and
(d)将β-丙氨酸钠溶于C1-8-醇中,获得具有期望浓度的β-丙氨酸钠在醇中的溶液。(d) Sodium β-alanine is dissolved in C 1-8 -alcohol to obtain a solution of sodium β-alanine in alcohol with the desired concentration.
在搅拌下向水中过量的氢氧化钠(例如约33w/w%溶液)中添加β-氨基-丙腈是有利的。添加β-氨基-丙腈的一个优选的温度范围是90-95℃。产生的氨可以在外部洗涤塔中以已知的方式被无机酸的水溶液吸收。It is advantageous to add β-amino-propionitrile to an excess of sodium hydroxide in water (eg about 33 w/w% solution) with stirring. A preferred temperature range for the addition of β-amino-propionitrile is 90-95°C. The ammonia produced can be absorbed by the aqueous mineral acid solution in a known manner in an external scrubber.
β-氨基-丙腈和氢氧化钠的优选的摩尔量在1∶1.01-10范围内,更优选地在1∶1.01-2.0范围内,最优选地在1∶1.03-1.1范围内。反应完成后,可以将反应混合物进一步加热,例如加热回流,并通过蒸馏去除至少部分水。在该操作期间,内部温度会升高。反应可以在大气压下进行或者在超大气压下进行,需要时在惰性气体下进行。The preferred molar amounts of β-amino-propionitrile and sodium hydroxide are in the range of 1:1.01-10, more preferably in the range of 1:1.01-2.0, most preferably in the range of 1:1.03-1.1. After the reaction is complete, the reaction mixture can be further heated, eg, to reflux, and at least part of the water removed by distillation. During this operation, the internal temperature will increase. The reaction can be carried out under atmospheric pressure or under superatmospheric pressure, if desired, under an inert gas.
剩余反应混合物中过量的氢氧化钠用β-丙氨酸中和。根据现有技术方法,该β-丙氨酸是购买的。然而,根据本发明,用于中和步骤(b)中过量氢氧化钠的β-丙氨酸由根据本发明的步骤(a)获得的部分β-丙氨酸钠通过离子交换,而得自该方法自身。该副步骤(side-step)使得整个方法在经济上更有吸引力。许多合适的离子交换树脂可以商业获得,并且可用于这一目的。Excess sodium hydroxide in the remaining reaction mixture was neutralized with β-alanine. According to prior art methods, the beta-alanine is purchased. However, according to the present invention, the β-alanine used to neutralize excess sodium hydroxide in step (b) is obtained by ion exchange from part of the sodium β-alanine obtained in step (a) according to the present invention from The method itself. This side-step makes the whole process more economically attractive. Many suitable ion exchange resins are commercially available and can be used for this purpose.
在适当直径的柱中,将β-丙氨酸盐溶液加载树脂上并用软化水洗涤树脂后,用水性无机酸再生树脂。当然,用于中和的β-丙氨酸也可以通过添加等量酸(优选地为水性无机酸)由其钠盐获得。In a column of appropriate diameter, the resin is regenerated with an aqueous mineral acid after loading the β-alanine salt solution onto the resin and washing the resin with demineralized water. Of course, the β-alanine used for neutralization can also be obtained from its sodium salt by adding an equivalent amount of acid (preferably an aqueous inorganic acid).
在本方法的中和步骤中,应当避免使用大幅过量的β-丙氨酸。这可以通过本领域公知的方法实现,例如通过滴定实现。优选地,获得60%β-丙氨酸钠水溶液。During the neutralization step of the method, large excesses of β-alanine should be avoided. This can be achieved by methods known in the art, for example by titration. Preferably, a 60% aqueous solution of sodium beta-alanine is obtained.
从β-丙氨酸钠溶液中去除剩余的水可以根据本领域公知的方法在常压或减压下实现,例如通过使用夹带剂的共沸蒸馏或如US 4.258.210中所述实现。如果使用该特定的两步骤水去除方法,则以下是有利的:在第一步骤中使用降膜蒸发器并在减压下蒸发至5-15%(w/w)的残余水含量,和在第二步骤中在甚至更低的压强下使用薄膜蒸发器蒸发至少于0.5%(w/w)、更优选地不超过0.20%(w/w)的残余水含量。第二蒸发步骤可以通过用氮汽提来完成。Removal of the remaining water from the sodium beta-alanine solution can be achieved at normal or reduced pressure according to methods known in the art, for example by azeotropic distillation using an entrainer or as described in US 4.258.210. If this particular two-step water removal method is used, it is advantageous to use a falling film evaporator in the first step and evaporate under reduced pressure to a residual water content of 5-15% (w/w), and A thin film evaporator is used in the second step at even lower pressure to evaporate to a residual water content of less than 0.5% (w/w), more preferably not more than 0.20% (w/w). The second evaporation step can be accomplished by stripping with nitrogen.
作为减压下两步骤水去除方法的结果,获得了高度纯净的β-丙氨酸钠的熔化物,所述熔化物在去除真空后溶于C1-8链烷醇中(优选甲醇或乙醇),得到β-丙氨酸钠在这类链烷醇中的1-40%(w/w)溶液,其含有不多于0.5%、优选地不多于0.2%(w/w)的水。术语“溶解的(dissolved)”和“溶解(dissolving)”分别包括“分散的(dispersed)”和“分散(dispersing)”。As a result of a two-step water removal process under reduced pressure, a highly pure melt of sodium β-alanine is obtained, which is dissolved in a C 1-8 alkanol (preferably methanol or ethanol after removal of the vacuum) ) to obtain a 1-40% (w/w) solution of sodium beta-alanine in such alkanols containing not more than 0.5%, preferably not more than 0.2% (w/w) of water . The terms "dissolved" and "dissolving" include "dispersed" and "dispersing", respectively.
由此获得或者能够由此获得的β-丙氨酸钠溶液(其本身代表了本发明的一个方面)可随后与R-泛内酯反应得到泛酸钠,所述泛酸钠任选地被转化为泛酸或其盐,优选钙盐,而不需要额外的结晶步骤。术语“溶液”和“溶解”包括“分散系/分散”。The sodium beta-alaninate solution thus obtained or capable of being obtained thereby (which itself represents an aspect of the invention) may subsequently be reacted with R-pantolactone to give sodium pantothenate, which is optionally converted to Pantothenic acid or a salt thereof, preferably a calcium salt, does not require an additional crystallization step. The terms "solution" and "dissolution" include "dispersion/dispersion".
根据本身已知的方法或其类似方法,分别获得了D-泛酸钙或D-泛酸钠,所述D-泛酸钠随后可以被转化为D-泛酸钙。Calcium D-pantothenate or sodium D-pantothenate, which can subsequently be converted into calcium D-pantothenate, respectively, is obtained according to methods known per se or methods analogous thereto.
可以从这些溶液中以高产率和下述纯度获得期望的D-泛酸钙,所述纯度满足用于人食品应用、人维生素制剂或药物配制物的制备中的规格。The desired calcium D-pantothenate can be obtained from these solutions in high yields and in a purity meeting specifications for human food applications, human vitamin preparations or preparation of pharmaceutical formulations.
根据上文和以下实施方式中所述的方法获得或能够获得的β-丙氨酸钠溶液以及D-泛酸钙是本发明的一个方面。The sodium β-alanine solution and calcium D-pantothenate obtained or obtainable according to the methods described above and in the following embodiments are an aspect of the present invention.
最后,根据本文所述的方法获得的D-泛酸钙在生产人食品和动物饲料应用、维生素制剂和药物配制物中的用途也是本发明的一个方面。Finally, the use of calcium D-pantothenate obtained according to the methods described herein for the production of human food and animal feed applications, vitamin preparations and pharmaceutical formulations is also an aspect of the present invention.
这类人食品和动物饲料应用、维生素制剂和药物配制物的生产方法是本领域技术人员公知的。Methods for the production of such human food and animal feed applications, vitamin preparations and pharmaceutical formulations are well known to those skilled in the art.
本发明通过以下的实施例更详细地阐述。除非另有说明,所有的百分比以w/w为基础。The invention is illustrated in more detail by the following examples. All percentages are on a w/w basis unless otherwise stated.
实施例1Example 1
从β-氨基丙腈生产β-丙氨酸钠Production of β-alanine sodium from β-aminopropionitrile
在63L不锈钢反应罐中,将13.34kg软化水(MW=18.02,740.29摩尔,2.6当量)和25.12kg水性NaOH(50%)(NaOH:MW=40.00,314.00摩尔,1.1当量;水:MW=18.02,697.00摩尔,2.4当量)的混合物加热至90℃的内部温度(IT)。在90-95℃的内部温度下,在30分钟的时间段内向该经预热的混合物中添加20.02gβ-氨基丙腈(APN)(MW=70.09,99.0w/w%,282.77摩尔,1.0当量)。在装有10%硫酸水溶液的外部洗涤塔中吸收产生的氨。In a 63L stainless steel reaction tank, 13.34kg of demineralized water (MW=18.02, 740.29 moles, 2.6 equivalents) and 25.12kg of aqueous NaOH (50%) (NaOH: MW=40.00, 314.00 moles, 1.1 equivalents; water: MW=18.02 , 697.00 mol, 2.4 eq) mixture was heated to an internal temperature (IT) of 90°C. To this preheated mixture was added 20.02 g of β-aminopropionitrile (APN) (MW=70.09, 99.0 w/w%, 282.77 moles, 1.0 eq. ). The ammonia produced is absorbed in an external scrubber with 10% aqueous sulfuric acid.
完成APN的添加后,将反应混合物在90℃的IT下搅拌45分钟。然后将反应混合物加热回流。在回流下从反应混合物中馏出6.57kg水。在水的蒸馏/回流下3.5小时后,通过HPLC分析反应混合物。After the addition of APN was complete, the reaction mixture was stirred at 90 °C IT for 45 min. The reaction mixture was then heated to reflux. 6.57 kg of water were distilled off from the reaction mixture under reflux. After 3.5 hours under distillation/reflux of water, the reaction mixture was analyzed by HPLC.
结果:β-丙氨酸:52.37w/w%;IDPA:0.68w/w%;二肽:0.02w/w%.Results: β-alanine: 52.37w/w%; IDPA: 0.68w/w%; dipeptide: 0.02w/w%.
获得46.45kg反应混合物(通过上述分析,产率为96.7%)。将反应混合物冷却至30℃的IT并分成两部分。其中40.88kg(88%)直接用于中和步骤,5.57kg(12%)用3.55kg软化水稀释,并用于离子交换步骤以生产β-丙氨酸。46.45 kg of the reaction mixture were obtained (96.7% yield by the above analysis). The reaction mixture was cooled to 30 °C IT and divided into two parts. Of which 40.88kg (88%) was directly used in the neutralization step, 5.57kg (12%) was diluted with 3.55kg demineralized water and used in the ion exchange step to produce β-alanine.
实施例2Example 2
通过离子交换生产β-丙氨酸Production of beta-alanine by ion exchange
在离子交换步骤中使用实施例1中生产的经稀释的反应混合物(9.0kg),用于产生β-丙氨酸溶液。The diluted reaction mixture (9.0 kg) produced in Example 1 was used in the ion exchange step for generating the β-alanine solution.
分析(HPLC):β-丙氨酸:32.01w/w%;IDPA:0.28w/w%;二肽:0.01w/w%。Analysis (HPLC): β-alanine: 32.01 w/w %; IDPA: 0.28 w/w %; dipeptide: 0.01 w/w %.
用4.5L的Rohm&Haas的Amberlyst 15(1.7mole/L,7.65摩尔)装填直径5.3cm的2.5m不锈钢柱,使用前用软化水洗涤。以300g/min的流速将Na-β-Ala进料溶液(feed solution)加料到柱中。A 2.5m stainless steel column with a diameter of 5.3cm was packed with 4.5L of Rohm&Haas Amberlyst 15 (1.7mole/L, 7.65 mole), and washed with demineralized water before use. The Na-β-Ala feed solution was fed to the column at a flow rate of 300 g/min.
使用该具体的装置,用该进料溶液进行五个循环。在每个循环后用10%硫酸溶液使柱再生,并且之后用水洗涤。Using this particular apparatus, five cycles were performed with the feed solution. The column was regenerated with 10% sulfuric acid solution after each cycle and washed with water afterwards.
将所有五个循环中含有用于中和的β-丙氨酸的主要级分合并,得到9.76kg。β-丙氨酸的回收率:95.6%。The major fractions containing β-alanine for neutralization from all five cycles were combined to give 9.76 kg. The recovery rate of β-alanine: 95.6%.
分析:β-丙氨酸:28.21w/w%;IDPA:0.35w/w%;二肽:0.01w/w%;钠(离子色谱[IC]):438ppm。Analysis: β-alanine: 28.21 w/w %; IDPA: 0.35 w/w %; dipeptide: 0.01 w/w %; sodium (ion chromatography [IC]): 438 ppm.
实施例3Example 3
过量NaOH的精确中和Precise neutralization of excess NaOH
在63L不锈钢罐中,用精确量的实施例2中获得的7.12kg β-丙氨酸溶液中和如实施例1中所述获得的38.57kg未经稀释的反应溶液的过量NaOH。在<27℃的IT下在30分钟期间添加β-丙氨酸溶液。In a 63 L stainless steel tank, 38.57 kg of the undiluted reaction solution obtained as described in Example 1 was neutralized with the exact amount of 7.12 kg of the β-alanine solution obtained in Example 2 with excess NaOH. The β-alanine solution was added during 30 minutes at IT at <27°C.
通过滴定反应溶液的小样测定β-丙氨酸溶液的需要量。β-丙氨酸过量2.50%的中和被认为是最适的。The required amount of beta-alanine solution was determined by titrating an aliquot of the reaction solution. Neutralization of β-alanine excess of 2.50% was considered optimal.
添加β-丙氨酸溶液后,将混合物再搅拌15分钟。获得45.69kg被中和的溶液。After addition of the β-alanine solution, the mixture was stirred for a further 15 minutes. 45.69 kg of neutralized solution were obtained.
结果:β-丙氨酸:48.26w/w%;IDPA:0.67w/w%:二肽:0.01w/w%。Results: β-alanine: 48.26w/w%; IDPA: 0.67w/w%: dipeptide: 0.01w/w%.
结果获得60.19%Na-β-Ala的水溶液。混合物中β-丙氨酸的过量为0.22%。As a result, an aqueous solution of 60.19% Na-β-Ala was obtained. The excess of β-alanine in the mixture was 0.22%.
实施例4Example 4
从水性β-丙氨酸钠溶液中去除水Removal of Water from Aqueous Sodium Beta-Alanine Solutions
将5.59kg/h的来自实施例3的β-丙氨酸钠溶液加料到带循环的降膜蒸发器中。降膜蒸发器在以下条件下运行;5.59 kg/h of the sodium β-alaninate solution from Example 3 were fed to the falling film evaporator with circulation. The falling film evaporator operates under the following conditions;
压强:175mbar。降膜温度:150℃。降膜底部温度:100℃。降膜循环温度:120℃。循环:20kg/h。Pressure: 175mbar. Falling film temperature: 150°C. Falling film bottom temperature: 100°C. Falling film cycle temperature: 120°C. Cycle: 20kg/h.
在降膜中从混合物中蒸馏1.65kg/h水。通过有护套的管(温度130℃)将浓缩物直接输入薄膜蒸发器。浓缩物具有以下组成(针对β-Ala和副产物的HPLC,平衡量的水):1.65 kg/h of water were distilled from the mixture in the falling film. The concentrate was fed directly to the thin-film evaporator via a sheathed tube (temperature 130°C). The concentrate had the following composition (HPLC for β-Ala and by-products, water in equilibrium):
分析:β-丙氨酸:66.75w/w%;IDPA:2.11w/w%;二肽:0.01w/w%;水:14.61w/w%。Analysis: β-alanine: 66.75w/w%; IDPA: 2.11w/w%; dipeptide: 0.01w/w%; water: 14.61w/w%.
将3.90kg/h浓缩物加料到薄膜蒸发器中。薄膜蒸发器使用以下的参数运行:3.90 kg/h of concentrate were fed to the thin film evaporator. The thin film evaporator was run with the following parameters:
压强:18mbar;薄膜温度:160℃;薄膜底部温度:150℃。Pressure: 18mbar; film temperature: 160°C; film bottom temperature: 150°C.
在薄膜蒸发器中从Na-β-Ala中蒸馏0.55kg/h水。0.55 kg/h of water were distilled from Na-β-Ala in a thin-film evaporator.
将来自薄膜蒸发器的熔化的β-丙氨酸钠直接加入装有5.78kg/h甲醇的63L不锈钢溶解罐中。将溶解罐的温度调节至5℃,导致熔化物溶解期间内部温度<25℃。The molten sodium β-alanine from the thin-film evaporator was directly fed into a 63 L stainless steel dissolution tank containing 5.78 kg/h methanol. The temperature of the dissolution tank was adjusted to 5°C, resulting in an internal temperature of <25°C during dissolution of the melt.
从溶解罐中获得9.16kg/h干燥的Na-β-Ala甲醇溶液。9.16 kg/h of dried Na-β-Ala methanol solution was obtained from the dissolution tank.
分析:β-丙氨酸:28.67w/w%;IDPA:1.41w/w%;二肽:0.01w/w%;水:0.19w/w%。Analysis: β-alanine: 28.67w/w%; IDPA: 1.41w/w%; dipeptide: 0.01w/w%; water: 0.19w/w%.
对总体两步骤干燥方法而言,针对β-丙氨酸计算的回收率为99.0%。The calculated recovery for β-alanine was 99.0% for the overall two-step drying process.
将该溶液直接用于泛酸钠缩合反应。This solution was directly used in the condensation reaction of sodium pantothenate.
Calpan的制备Preparation of Calpan
将100g干燥的Na-β-Ala甲醇溶液(321.8mmole)与41.9g(321.8mmole)R-泛内酯反应,获得D-泛酸钠溶液。100 g of dried Na-β-Ala methanol solution (321.8 mmole) was reacted with 41.9 g (321.8 mmole) of R-pantolactone to obtain a solution of sodium D-pantothenate.
根据本领域技术人员已知的方法进行后处理,所述后处理包括从钠到钙的离子交换。Workup is carried out according to methods known to those skilled in the art, said workup comprising ion exchange from sodium to calcium.
Calpan产物:79.64g,163.93mmole。产率:93.6%。Calpan product: 79.64 g, 163.93 mmole. Yield: 93.6%.
分析:analyze:
泛酸钙 98.09w/w%Calcium pantothenate 98.09w/w%
泛解酸钙 0.59w/w%Calcium pantothenate 0.59w/w%
pant-β-Ala-β-Ala钙 0.02w/w%pant-β-Ala-β-Ala Calcium 0.02w/w%
水 ad 100w/w%Water ad 100w/w%
实施例5Example 5
用氮从水性β-丙氨酸钠溶液中去除水Removal of Water from Aqueous Sodium β-Alanine Solutions Using Nitrogen
这一步骤使用不同的水性β-丙氨酸钠溶液。用于水去除的初始材料具有过量3.4%的β-丙氨酸中和,并且被分析为含有:β-丙氨酸:46.41w/w%;IDPA:1.69w/w%;二肽:0.06w/w%。This step uses a different aqueous sodium β-alanine solution. The starting material for water removal had an excess of 3.4% neutralization of β-alanine and was analyzed to contain: β-alanine: 46.41 w/w%; IDPA: 1.69 w/w%; dipeptide: 0.06 w/w%.
将5.75kg/h该溶液加料到带有循环的降膜蒸发器中。降膜蒸发器在以下条件下运行:5.75 kg/h of this solution were fed to a falling film evaporator with circulation. Falling film evaporators operate under the following conditions:
压强:175mbar。降膜温度:150℃。降膜底部温度:100℃。降膜循环温度:120℃。循环:20kg/h。Pressure: 175mbar. Falling film temperature: 150°C. Falling film bottom temperature: 100°C. Falling film cycle temperature: 120°C. Cycle: 20kg/h.
在降膜中从混合物中蒸馏1.86kg/h水。通过有护套的管(温度130℃)将浓缩物直接输入薄膜蒸发器。浓缩物具有以下组成(针对β-Ala和副产物的HPLC,平衡量的水):1.86 kg/h of water were distilled from the mixture in the falling film. The concentrate was fed directly to the thin-film evaporator via a sheathed tube (temperature 130°C). The concentrate had the following composition (HPLC for β-Ala and by-products, water in equilibrium):
分析:β-丙氨酸:68.59w/w%;IDPA:1.94w/w%;二肽:0.09w/w%;水:11.55w/w%。Analysis: β-alanine: 68.59w/w%; IDPA: 1.94w/w%; dipeptide: 0.09w/w%; water: 11.55w/w%.
将3.90kg/h浓缩物加料到薄膜蒸发器中。薄膜蒸发器在以下条件下运行:3.90 kg/h of concentrate were fed to the thin film evaporator. Thin film evaporators operate under the following conditions:
压强:22mbar;薄膜温度:160℃;薄膜底部温度:150℃。Pressure: 22mbar; film temperature: 160°C; film bottom temperature: 150°C.
在薄膜蒸发器底部进料氮:30L/h。Nitrogen feed at the bottom of the thin film evaporator: 30 L/h.
在薄膜蒸发器中馏出0.41kg/h水。将来自薄膜蒸发器的熔化的β-丙氨酸钠直接加入装有5.85kg/h甲醇的63L不锈钢溶解罐中。将溶解罐的温度调节至5℃,导致熔化物溶解期间内部温度<25℃。0.41 kg/h of water were distilled off in the thin-film evaporator. The molten sodium β-alanine from the thin film evaporator was directly added to a 63 L stainless steel dissolution tank containing 5.85 kg/h methanol. The temperature of the dissolution tank was adjusted to 5°C, resulting in an internal temperature of <25°C during dissolution of the melt.
从溶解罐中获得9.27kg/h干燥的Na-β-Ala甲醇溶液。9.27 kg/h of dried Na-β-Ala methanol solution was obtained from the dissolution tank.
分析:β-丙氨酸:28.82w/w%;IDPA:1.28w/w%;二肽:0.04w/w%;水:0.09w/w%。Analysis: β-alanine: 28.82w/w%; IDPA: 1.28w/w%; dipeptide: 0.04w/w%; water: 0.09w/w%.
对总体两步骤干燥方法而言,针对β-丙氨酸计算的回收率是定量的。将该溶液直接用于泛酸钠缩合反应。The calculated recoveries for β-alanine are quantitative for the overall two-step drying method. This solution was directly used in the condensation reaction of sodium pantothenate.
Calpan的制备Preparation of Calpan
将100g干燥的Na-β-Ala甲醇溶液(323.4mmole)与42.1g(323.4mmole)R-泛内酯反应,获得D-泛酸钠溶液。100 g of dried Na-β-Ala methanol solution (323.4 mmole) was reacted with 42.1 g (323.4 mmole) of R-pantolactone to obtain a solution of sodium D-pantothenate.
根据本领域技术人员已知的方法进行后处理,所述后处理包括从钠到钙的离子交换。Workup is carried out according to methods known to those skilled in the art, said workup comprising ion exchange from sodium to calcium.
Calpan产物:79.78g,160.68mmole。产率:92.9%。Calpan product: 79.78 g, 160.68 mmole. Yield: 92.9%.
分析:analyze:
泛酸钙 99.73w/w%Calcium pantothenate 99.73w/w%
泛解酸钙 0.25w/w%Calcium pantothenate 0.25w/w%
pant-β-Ala-β-Ala钙 0.08w/w%pant-β-Ala-β-Ala Calcium 0.08w/w%
水 ad 100w/w%Water ad 100w/w%
实施例6Example 6
过量OH的过度中和Overneutralization of excess OH
在63L不锈钢罐中,用8.91kg β-丙氨酸溶液中和40.88kg未经稀释的反应溶液(来自以与实施例1相同的方式进行的水解步骤)的过量NaOH,所述反应溶液含有:β-丙氨酸,51.80w/w%;IDPA n.a.和二肽,0.17w/w%;所述β-丙氨酸溶液被分析为含有:β-丙氨酸,26.91w/w%;IDPA n.a.;二肽,0.03w/w%;钠(IC),380ppm。In a 63 L stainless steel tank, 8.91 kg of β-alanine solution was used to neutralize the excess NaOH of 40.88 kg of the undiluted reaction solution (from the hydrolysis step performed in the same manner as in Example 1) containing: β-alanine, 51.80w/w%; IDPA n.a. and dipeptide, 0.17w/w%; the β-alanine solution was analyzed to contain: β-alanine, 26.91w/w%; IDPA n.a.; dipeptide, 0.03 w/w %; sodium (IC), 380 ppm.
在<27℃的IT下在30分钟期间添加β-丙氨酸溶液。The β-alanine solution was added during 30 minutes at IT at <27°C.
根据滴定,这是β-丙氨酸过量21.5%的中和。According to the titration, this is the neutralization of 21.5% of the beta-alanine excess.
添加β-丙氨酸溶液后,将混合物再搅拌15分钟。获得49.49kg中和的溶液。After addition of the β-alanine solution, the mixture was stirred for a further 15 minutes. 49.49 kg of neutralized solution were obtained.
结果:β-丙氨酸:47.37w/w%、IDPA:0.70w/w%、二肽:0.02w/w%。Results: β-alanine: 47.37w/w%, IDPA: 0.70w/w%, dipeptide: 0.02w/w%.
混合物中β-丙氨酸过量2.02w/w%。The excess of β-alanine in the mixture was 2.02w/w%.
实施例7Example 7
从过度中和的水性β-丙氨酸钠溶液中去除水Removal of Water from Overneutralized Aqueous Sodium Beta-Alanine Solutions
将来自实施例6的7.29kg/h过度中和的β-丙氨酸钠溶液加料到带循环的降膜蒸发器中。降膜蒸发器在以下条件下运行:7.29 kg/h of overneutralized sodium β-alaninate solution from Example 6 was fed to a falling film evaporator with circulation. Falling film evaporators operate under the following conditions:
压强:175mbar。降膜温度:150℃。降膜底部温度:100℃。降膜循环温度:120℃。循环:20kg/h。Pressure: 175mbar. Falling film temperature: 150°C. Falling film bottom temperature: 100°C. Falling film cycle temperature: 120°C. Cycle: 20kg/h.
在降膜中从混合物中馏出2.23kg/h水。通过有护套的管(温度130℃)将浓缩物直接输入薄膜蒸发器。浓缩物具有以下组成(针对β-Ala和副产物的HPLC,平衡量的水):2.23 kg/h of water were distilled from the mixture in the falling film. The concentrate was fed directly to the thin-film evaporator via a sheathed tube (temperature 130°C). The concentrate had the following composition (HPLC for β-Ala and by-products, water in equilibrium):
分析:β-丙氨酸:64.16w/w%;IDPA:0.34w/w%;二肽:0.05w/w%;水:13.49w/w%。Analysis: β-alanine: 64.16w/w%; IDPA: 0.34w/w%; dipeptide: 0.05w/w%; water: 13.49w/w%.
将5.06kg/h浓缩物加料到薄膜蒸发器中。薄膜蒸发器使用以下的参数运行:5.06 kg/h of concentrate were fed to the thin film evaporator. The thin film evaporator was run with the following parameters:
压强:29mbar;薄膜温度:160℃;薄膜底部温度:150℃。Pressure: 29mbar; film temperature: 160°C; film bottom temperature: 150°C.
在薄膜蒸发器底部加入氮:40L/h。Add nitrogen at the bottom of the thin film evaporator: 40L/h.
在薄膜蒸发器中馏出0.57kg/h水。将来自薄膜蒸发器的熔化的β-丙氨酸钠直接加入装有7.39kg/h甲醇的63L不锈钢溶解罐中。将溶解罐的温度调节至5℃,导致熔化物溶解期间内部温度<25℃。0.57 kg/h of water distilled off in the thin-film evaporator. The molten sodium β-alanine from the thin film evaporator was directly fed into a 63 L stainless steel dissolution tank containing 7.39 kg/h methanol. The temperature of the dissolution tank was adjusted to 5°C, resulting in an internal temperature of <25°C during dissolution of the melt.
从溶解罐中获得11.69kg/h干燥的Na-β-Ala甲醇溶液。11.69 kg/h of dried Na-β-Ala methanol solution was obtained from the dissolution tank.
分析:β-丙氨酸:27.02w/w%;IDPA:0.29w/w%;二肽:0.07w/w%;水:0.15w/w%。Analysis: β-alanine: 27.02w/w%; IDPA: 0.29w/w%; dipeptide: 0.07w/w%; water: 0.15w/w%.
对总体两步骤干燥方法而言,针对β-丙氨酸计算的回收率是91.5%。The calculated recovery for β-alanine was 91.5% for the overall two-step drying process.
将该溶液直接用于泛酸钠缩合反应。This solution was directly used in the condensation reaction of sodium pantothenate.
Calpan的制备Preparation of Calpan
将100g干燥的Na-β-Ala甲醇溶液(303.3mmole)与39.5g(303.8mmole)R-泛内酯反应,获得D-泛酸钠溶液。100 g of dried Na-β-Ala methanol solution (303.3 mmole) was reacted with 39.5 g (303.8 mmole) of R-pantolactone to obtain a solution of sodium D-pantothenate.
根据本领域技术人员已知的方法进行后处理,所述后处理包括从钠到钙的离子交换。Workup is carried out according to methods known to those skilled in the art, said workup comprising ion exchange from sodium to calcium.
Calpan产物:79.19g,160.06mmole。产率:94.3%。Calpan product: 79.19 g, 160.06 mmole. Yield: 94.3%.
分析;analyze;
泛酸钙 96.32w/w%Calcium pantothenate 96.32w/w%
泛解酸钙 0.14w/w%Calcium pantothenate 0.14w/w%
pant-β-Ala-β-Ala钙0.16w/w%(比实施例4和5中明显更高)pant-β-Ala-β-Ala calcium 0.16w/w% (significantly higher than in Examples 4 and 5)
水 ad 100w/w%Water ad 100w/w%
实施例8Example 8
二肽降解不完全的反应,1.1当量NaOH未中和Incomplete dipeptide degradation reaction, 1.1 N NaOH is not neutralized
在室温下将21.7g氢氧化钠丸粒(540.2mmole,1.1当量)溶于45.1g软化水(2503.0mmole,5.1当量)中。将溶液加热至90℃的IT。在该温度下开始添加35.0g氨基丙腈(490.5mmole,1.0当量)。APN的添加在30分钟内完成。然后将反应混合物在90℃ IT下搅拌10.5小时。21.7 g of sodium hydroxide pellets (540.2 mmole, 1.1 equiv) were dissolved in 45.1 g of demineralized water (2503.0 mmole, 5.1 equiv) at room temperature. The solution was heated to an IT of 90 °C. At this temperature the addition of 35.0 g of aminopropionitrile (490.5 mmole, 1.0 equiv) was started. The addition of the APN is done within 30 minutes. The reaction mixture was then stirred at 90° C. IT for 10.5 hours.
分析:β-丙氨酸:48.54w/w%;IDPA:0.15w/w%;二肽:0.21w/w%。Analysis: β-alanine: 48.54w/w%; IDPA: 0.15w/w%; dipeptide: 0.21w/w%.
将45.11g反应混合物(来自总计93.5g;246.0mmolβ-丙氨酸钠)放入旋转蒸发器中。在60℃的温育温度和700-600mbar的减压下,去除剩余的氨和大部分水。分三部分,向水性悬浮液中添加总量147.4g的正丁醇。在每次正丁醇添加后用旋转蒸发器共沸(azeotropically)去除正丁醇/水,得到68.6g蜡状固体。将固体溶于49.5g甲醇中。45.11 g of the reaction mixture (from a total of 93.5 g; 246.0 mmol sodium β-alanine) was placed in a rotary evaporator. At an incubation temperature of 60°C and a reduced pressure of 700-600 mbar, the remaining ammonia and most of the water were removed. A total of 147.4 g of n-butanol was added to the aqueous suspension in three portions. The n-butanol/water was azeotropically removed with a rotary evaporator after each n-butanol addition to yield 68.6 g of a waxy solid. The solid was dissolved in 49.5 g methanol.
分析:β-丙氨酸:19.13w/w%;IDPA:0.05w/w%:二肽:0.07w/w%;水0.20w/w%。253.9mmole β-丙氨酸,产率:103.2%Analysis: β-alanine: 19.13w/w%; IDPA: 0.05w/w%: dipeptide: 0.07w/w%; water 0.20w/w%. 253.9 mmole β-alanine, yield: 103.2%
Calpan的制备Preparation of Calpan
将110.5g干燥的Na-β-Ala甲醇溶液(237.4mmole)与31.2g(237.3mmole)R-泛内酯反应,获得D-泛酸钠溶液。110.5 g of dried Na-β-Ala methanol solution (237.4 mmole) was reacted with 31.2 g (237.3 mmole) of R-pantolactone to obtain a sodium D-pantothenate solution.
根据本领域技术人员已知的方法进行后处理,所述后处理包括从钠到钙的离子交换。Workup is carried out according to methods known to those skilled in the art, said workup comprising ion exchange from sodium to calcium.
Calpan产物:56.71g,110.00mmole。产率:83.2%。Calpan product: 56.71 g, 110.00 mmole. Yield: 83.2%.
分析:analyze:
泛酸钙 92.72w/w%Calcium pantothenate 92.72w/w%
泛解酸钙 3.06w/w%(比实施例4、5、7中明显更高)Calcium pantoate 3.06w/w% (obviously higher than in Examples 4, 5, and 7)
pant-β-Ala-β-Ala钙 0.19w/w%(比实施例4和5中明显更高)pant-β-Ala-β-Ala calcium 0.19w/w% (obviously higher than in Examples 4 and 5)
水 ad 100w/w%Water ad 100w/w%
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610118582.2A CN105669481B (en) | 2007-07-31 | 2008-07-15 | The method for synthesizing Beta-alanine sodium and calcium pantothenate |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07014971 | 2007-07-31 | ||
| EP07014971.1 | 2007-07-31 | ||
| PCT/EP2008/059201 WO2009016025A1 (en) | 2007-07-31 | 2008-07-15 | Process for the synthesis of na- beta-alaninate and calcium pantothenate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610118582.2A Division CN105669481B (en) | 2007-07-31 | 2008-07-15 | The method for synthesizing Beta-alanine sodium and calcium pantothenate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101801915A true CN101801915A (en) | 2010-08-11 |
Family
ID=40010925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610118582.2A Active CN105669481B (en) | 2007-07-31 | 2008-07-15 | The method for synthesizing Beta-alanine sodium and calcium pantothenate |
| CN200880101427A Pending CN101801915A (en) | 2007-07-31 | 2008-07-15 | Method for synthesizing beta-sodium alanine and calcium pantothenate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610118582.2A Active CN105669481B (en) | 2007-07-31 | 2008-07-15 | The method for synthesizing Beta-alanine sodium and calcium pantothenate |
Country Status (4)
| Country | Link |
|---|---|
| JP (3) | JP5534224B2 (en) |
| CN (2) | CN105669481B (en) |
| DE (1) | DE112008001983B4 (en) |
| WO (1) | WO2009016025A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102827010A (en) * | 2012-08-31 | 2012-12-19 | 江苏兄弟维生素有限公司 | Novel beta-aminopropanoic acid synthesis technology |
| CN103145579A (en) * | 2013-02-20 | 2013-06-12 | 山西普德药业股份有限公司 | Sodium pantothenate compound, and composition preparation containing it |
| CN110105235A (en) * | 2019-05-31 | 2019-08-09 | 珠海润都制药股份有限公司 | A kind of preparation method of high-purity sodium pantothenate |
| CN117567306A (en) * | 2023-11-13 | 2024-02-20 | 万华化学集团股份有限公司 | A method for efficiently preparing calcium beta-aminopropionate from beta-aminopropionitrile |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105669481B (en) * | 2007-07-31 | 2018-09-18 | 帝斯曼知识产权资产管理有限公司 | The method for synthesizing Beta-alanine sodium and calcium pantothenate |
| CN104592053B (en) * | 2015-01-16 | 2016-08-17 | 河北一品制药有限公司 | A kind of industrialized process for preparing of high-purity sodium pantothenate |
| EP3765438A1 (en) | 2018-03-13 | 2021-01-20 | Taminco Bvba | Process for drying n,n-dimethyl glycinate salt |
| EP3765437B1 (en) * | 2018-03-13 | 2023-12-20 | Taminco BV | Methods of stabilizing and purifying aqueous compositions of alkali metal salts of amino acids comprising alkali metal hydroxide |
| CN110257464A (en) * | 2019-07-12 | 2019-09-20 | 抚顺顺特化工有限公司 | A kind of preparation method of D-VB5 calcium |
| CN111440080A (en) * | 2020-05-22 | 2020-07-24 | 安徽安力肽生物科技有限公司 | Preparation method of high-purity β -sodium alanine |
| CN118910424B (en) * | 2024-07-15 | 2025-04-18 | 广东中耀环境科技有限公司 | A method for recovering metal from nickel-containing waste liquid |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS49110626A (en) * | 1973-03-07 | 1974-10-22 | ||
| US4258210A (en) * | 1978-05-18 | 1981-03-24 | Hoffmann-La Roche Inc. | Process for manufacturing sodium pantothenate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5216096B2 (en) * | 1972-04-26 | 1977-05-06 | ||
| JPS4913115A (en) * | 1972-06-02 | 1974-02-05 | ||
| US3935256A (en) | 1974-09-06 | 1976-01-27 | Thompson-Hayward Chem. Co. | Process for the production of the calcium salt of pantothenic acid |
| JP2891744B2 (en) * | 1989-04-19 | 1999-05-17 | 武田薬品工業株式会社 | Calcium pantothenate composition and method for producing the same |
| JP2002272430A (en) * | 2001-03-22 | 2002-09-24 | Nippon Yakuhin Kenkyusho Kk | Health beverage |
| JPWO2005105731A1 (en) * | 2004-04-30 | 2008-05-15 | 第一ファインケミカル株式会社 | New crystalline calcium pantothenate |
| CN105669481B (en) * | 2007-07-31 | 2018-09-18 | 帝斯曼知识产权资产管理有限公司 | The method for synthesizing Beta-alanine sodium and calcium pantothenate |
-
2008
- 2008-07-15 CN CN201610118582.2A patent/CN105669481B/en active Active
- 2008-07-15 WO PCT/EP2008/059201 patent/WO2009016025A1/en not_active Ceased
- 2008-07-15 CN CN200880101427A patent/CN101801915A/en active Pending
- 2008-07-15 DE DE112008001983.5T patent/DE112008001983B4/en active Active
- 2008-07-15 JP JP2010518600A patent/JP5534224B2/en not_active Expired - Fee Related
-
2014
- 2014-01-23 JP JP2014010414A patent/JP2014098003A/en active Pending
-
2015
- 2015-10-28 JP JP2015212009A patent/JP6029729B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS49110626A (en) * | 1973-03-07 | 1974-10-22 | ||
| US4258210A (en) * | 1978-05-18 | 1981-03-24 | Hoffmann-La Roche Inc. | Process for manufacturing sodium pantothenate |
Non-Patent Citations (1)
| Title |
|---|
| TOMASZ ROWICKI ET AL: "Calcium Pantothenate. Part 1. (R,S)-Pantolactone Technology Improvement at the Tonnage Scale", 《IND. ENG. CHEM. RES.》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102827010A (en) * | 2012-08-31 | 2012-12-19 | 江苏兄弟维生素有限公司 | Novel beta-aminopropanoic acid synthesis technology |
| CN102827010B (en) * | 2012-08-31 | 2014-07-30 | 江苏兄弟维生素有限公司 | Novel beta-aminopropanoic acid synthesis technology |
| CN103145579A (en) * | 2013-02-20 | 2013-06-12 | 山西普德药业股份有限公司 | Sodium pantothenate compound, and composition preparation containing it |
| CN103145579B (en) * | 2013-02-20 | 2014-12-17 | 山西普德药业股份有限公司 | Sodium pantothenate compound, and composition preparation containing it |
| CN110105235A (en) * | 2019-05-31 | 2019-08-09 | 珠海润都制药股份有限公司 | A kind of preparation method of high-purity sodium pantothenate |
| CN110105235B (en) * | 2019-05-31 | 2022-07-08 | 珠海润都制药股份有限公司 | Preparation method of high-purity sodium pantothenate |
| CN117567306A (en) * | 2023-11-13 | 2024-02-20 | 万华化学集团股份有限公司 | A method for efficiently preparing calcium beta-aminopropionate from beta-aminopropionitrile |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010534700A (en) | 2010-11-11 |
| DE112008001983T5 (en) | 2010-06-10 |
| CN105669481B (en) | 2018-09-18 |
| WO2009016025A1 (en) | 2009-02-05 |
| JP2016047833A (en) | 2016-04-07 |
| DE112008001983B4 (en) | 2023-08-10 |
| JP6029729B2 (en) | 2016-11-24 |
| CN105669481A (en) | 2016-06-15 |
| JP5534224B2 (en) | 2014-06-25 |
| JP2014098003A (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105669481B (en) | The method for synthesizing Beta-alanine sodium and calcium pantothenate | |
| TW502011B (en) | Process for producing n-long-chain acyl acidic amino acids or salts thereof | |
| JP2016528271A (en) | □ Synthesis of biphenylalaninol via a novel intermediate | |
| CN101778824A (en) | Process for producing toluidine compound | |
| CN108314688B (en) | A kind of synthetic method of sitagliptin | |
| Gmeiner | An efficient and practical EPC synthesis of β‐amino acids from L‐asparagine | |
| US9932295B2 (en) | Process for preparation of levothyroxine and salts thereof | |
| JPH05117169A (en) | Production method of chloromethyl ketone | |
| WO2003002517A1 (en) | Process for the preparation of 1.1-cyclohexane diacetic acid monoamide | |
| CN108409589A (en) | A kind of preparation method of the beta-amino acid esters of band chirality | |
| JP4922152B2 (en) | Method for producing fluorinated proline derivative | |
| US20060264671A1 (en) | Process for the preparation of midodrine, pharmaceutically acceptable salts thereof and intermediates | |
| JP2003137850A (en) | Method for producing amino acid ester hydrochloride | |
| EP1603863B1 (en) | Process for the preparation of amino methyl cyclo alkane acetic acids | |
| JPS6011448A (en) | Manufacture of hydrazinocarboxylic acid derivative by n-amination of aminocarboxylic acid derivative | |
| CN113292495B (en) | Synthesis method of (S) -amino compound | |
| JP4699582B2 (en) | Method for producing 1H-4 (5) -aminoimidazole-5 (4) -carboxamide | |
| AU728197B2 (en) | Preparation of alpha-amino carboxylic acid amides | |
| Pajpanova | A simple and convenient procedure for the preparation of 3, 5-dihalogenated tyrosine derivatives useful in peptide synthesis | |
| JPH0798783B2 (en) | Process for producing N, N-dimethyl-α-amino chain fatty acid | |
| CN115028611A (en) | Method for synthesizing 4-aminotetrahydro-2-pyran-4-carboxylic acid | |
| JP4438184B2 (en) | Process for producing N-protected N-alkylated amino acids | |
| JPS6327465A (en) | Production of glycinamide | |
| JPH11199542A (en) | Production of complex salt of organic acid and amine | |
| WO2002064623A1 (en) | Process for preparation of peptide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100811 |